INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi ®, a biosimilar referencing Humira ® 1 (adalimumab), for the treatment of ...
Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...
Posters presented at the EADV Congress highlighted that despite similar efficacy, patient perception can affect satisfaction with the switch from the reference adalimumab to a biosimilar. While ...
Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...
* Secondary endpoints demonstrated that Imraldi has a comparable safety and immunogenicity profile to Humira * Primary endpoint of phase III study, ACR20 response at week 24, was met, demonstrating ...
Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback